特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
940103

がん免疫診断市場:カスタム型の予測・分析、新型コロナウイルス感染症 (Covid-19) の影響、エグゼクティブ・コンサルタント向け提言 (2020~2024年)

Immuno-Oncology Diagnostics Market Forecasts for Immuno-Oncology Diagnostics with COVID-19 Impact and Updates. Including Executive/Consultant Guides and Customized Forecasting/Analysis. 2020 to 2024

出版日: | 発行: Howe Sound Research | ページ情報: 英文 254 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
がん免疫診断市場:カスタム型の予測・分析、新型コロナウイルス感染症 (Covid-19) の影響、エグゼクティブ・コンサルタント向け提言 (2020~2024年)
出版日: 2020年06月04日
発行: Howe Sound Research
ページ情報: 英文 254 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、がん免疫診断の今後の技術進歩・市場成長の見通しについて分析し、技術的な概略や主な活用分野、今後の医療現場に及ぼす影響力、昨今の主な開発・製品上市の動き、主要企業のプロファイルと主力製品、今後の市場規模の動向見通し、地域別・アッセイの種類別の詳細動向、新型コロナウイルス感染症 (Covid-19) 発生の影響、といった情報を取りまとめてお届けいたします。

目次

i. コンパニオン診断市場:戦略的状況分析

i. 市場概略

i. 状況分析と、新型コロナウイルス感染症 (Covid-19) 感染拡大の影響

ii. エグゼクティブ・マーケティングスタッフ向け提言

iii. 経営コンサルタント・投資顧問向け提言

第1章 イントロダクション、市場の定義

第2章 免疫療法:免疫技術の概略

  • 免疫システム
    • 自然免疫システム
    • 適応免疫システム
    • 腫瘍免疫学-免疫監視システム
  • 免疫腫瘍学診断
    • チェックポイントアッセイ
    • サイトカインアッセイ
    • 生殖細胞系列遺伝子
    • ゲノム腫瘍
    • 腫瘍微小環境
    • その他

第3章 市場概要

  • ダイナミックな市場における参入企業
    • 教育・研究機関
    • 診断検査の開発業者
    • 計測装置のサプライヤー
    • 試薬の流通業者・サプライヤー
    • 独立系の検査室
    • 国営/公営の検査室
    • 院内検査室
    • 開業医
    • 監査機関
    • 認証機関

第4章 市場動向

  • 市場成長の促進要因
  • 市場成長の抑制要因
  • 計装と自動化
  • 診断技術の開発

第5章 がん免疫療法:近年の進捗状況

  • 当セクションの重要性と活用方法

第6章 免疫療法:主要企業のプロフィール

  • 10X Genomics
  • Abbott Laboratories
  • Abcam
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience
  • Angle plc
  • Apocell
  • ARUP Laboratories
  • Beckman Coulter
  • Becton Dickinson
  • Bioarray Genetics
  • BioCartis
  • Biocept
  • Biodesix Inc
  • BioFluidica
  • BioGenex
  • bioMérieux
  • Bio-Rad
  • Bio-Techne
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clearbridge BioMedics
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp
  • CytoTrack
  • Dako (Agilent)
  • Diagnologix LLC
  • Epic Sciences
  • Exosome Diagnostics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • Genomic Health
  • GenomOncology
  • GRAIL
  • Guardant Health
  • HalioDx
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invivoscribe
  • Leica Biosystems
  • Luminex
  • MDx Health
  • Merck & Co., Inc
  • MIODx
  • Molecular MD
  • MRM Proteomics Inc
  • Myriad Genetics/Myriad RBM
  • Nanostring
  • Natera
  • Neogenomics
  • New Oncology
  • Oncocyte
  • Ortho Clinical Diagnostics
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Pfizer
  • Promega
  • Protagen Diagnostics
  • Qiagen
  • Quanterix
  • Rarecells SAS
  • Roche Diagnostics
  • Siemens
  • Silicon Biosystems
  • SkylineDx
  • SRI International
  • シスメックス
  • Thermo Fisher
  • Trovagene
  • Vortex Biosciences

第7章 世界のがん免疫診断市場

  • 国別分析:概要
  • アッセイの種類別分析:概要

第8章 世界のがん免疫診断市場:アッセイの種類別

  • チェックポイント
  • サイトカイン
  • 生殖細胞系列遺伝子
  • 遺伝性腫瘍
  • 腫瘍微小環境
  • その他

第9章 付録

図表

Table of Tables

  • Table 1: List of Cancers by Mortality
  • Table 2: Lab Spending 2014 to 2024
  • Table 3: Overview of Innate and Adaptive Immunity
  • Table 4: FDA Approved Monoclonal Antibodies in Cancer treatment
  • Table 5: FDA Approved Companion diagnostics in Cancer treatment
  • Table 6: Market Players by Type
  • Table 7: Five Factors Driving Growth
  • Table 8: Three Factors Limiting Growth
  • Table 9: - Global Market by Region
  • Table 10: Global Market by Assay Type
  • Table 11: Checkpoint by Country
  • Table 12: Cytokine by Country
  • Table 13: Germline Genetic by Country
  • Table 14: Genetic Tumor by Country
  • Table 15: Tumor Microenvironment by Country
  • Table 16: Other by Country

Table of Figures

  • Figure 1: Cancer Death Rates - USA, CDC
  • Figure 2: Clinical Lab Spending 2014 to 2024
  • Figure 3: Helper T Cell Roles
  • Figure 4: Antibody Diagram
  • Figure 5: Macrophages attack a Cancer Cell
  • Figure 6: The Tumour Micro Environment
  • Figure 7: Comparing IO Diagnostic and Traditional Testing
  • Figure 8: Growth rates of IO DiagnosticTechnologies
  • Figure 9: Global Market Density Chart
  • Figure 10: Global Market by Assay Type - Base vs. Final
  • Figure 11: Global Market by Assay Type Base Year
  • Figure 12: Global Market by Assay Type End Year
  • Figure 13: Assay Type Share by Year
  • Figure 14: Assay Type Segments Growth
  • Figure 15: Checkpoint Growth
  • Figure 16: Cytokine Growth
  • Figure 17: Germline Genetic Growth
  • Figure 18: Genetic Tumor Growth
  • Figure 19: Tumor Microenvironment Growth
  • Figure 20: Other Growth
  • Figure 21: FDA Cancer Drug Approvals by Year
  • Figure 22: Clinical Trials for Immunotherapy by Year
  • Figure 23: Pie Chart of Prevalence of Cancer Treatments
目次

OVERVIEW:

Revolution in cancer therapy to be driven by new diagnostics. Histology, genomics and liquid biopsy converge. COVID-19 changes focus.

This is a complex area but this readable report will bring the entire management team up to speed, on both the technology and the opportunity.

A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. But diagnostics, especially biomarkers are desperately needed to help select the right therapy.

The technology is moving faster than the market. The impact on the health care industry is enormous. Tumor Mutational Burden? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Market Guides

i. Situation Analysis & Impact of COVID-19 Pandemic

ii. Guide for Executives and Marketing Staff

iii. Guide for Investment Analysts and Management Consultants

1. Introduction and Market Definition

  • 1.1. What are Immuno-Oncology Diagnostics?
  • 1.2. Immuno-oncology - the looming cure
    • 1.2.1. Immuno-oncology Diagnostics Takes a Leading Role
  • 1.3. Market Definition
    • 1.3.1. Market Size
    • 1.3.2. Currency
    • 1.3.3. Years
  • 1.4. Methodology
    • 1.4.1. Authors
    • 1.4.2. Sources
  • 1.5. U.S. Medical Market and laboratory Testing - Perspective
    • 1.5.1. U.S. Medicare Expenditures for Laboratory Testing

2. Immunotherapy - Guide to Immune Technologies

  • 2.0. The Immune System
    • 2.0.1. Innate immune system
      • 2.0.1.1. Surface barriers
      • 2.0.1.2. Inflammation
      • 2.0.1.3. Complement system
      • 2.0.1.4. Cellular barriers
      • 2.0.1.5. Natural killer cells
    • 2.0.2. Adaptive immune system
      • 2.0.2.1. Lymphocytes
      • 2.0.2.2. Killer T cells
      • 2.0.2.3. Helper T cells
      • 2.0.2.4. Gamma delta T cells
      • 2.0.2.5. B lymphocytes and antibodies
    • 2.0.3. Tumor immunology - the immune surveillance system
  • 2.1. Immuno Oncology Diagnostics
    • 2.1.1. Checkpoint Assays
      • 2.1.1.1. Outlook for Checkpoint Assays
    • 2.1.2. Cytokine Assays
      • 2.1.2.1. Outlook for Cytokine Assays
    • 2.1.3. Genomic Germline
      • 2.1.3.1. Outlook for Genomic Germline
    • 2.1.4. Genomic Tumour
      • 2.1.4.1. Outlook for Genomic Tumour
    • 2.1.5. Tumor Microenviroment
      • 2.1.5.1. Outlook for Tumor Micro Environment
    • 2.1.6. Others
      • 2.1.6.1. Outlook for Other Diagnostics

3. Industry Overview

  • 3.1. Players in a Dynamic Market
    • 3.1.1. Academic Research Lab
    • 3.1.2. Diagnostic Test Developer
    • 3.1.3. Genomic Instrumentation Supplier
      • 3.1.3.1. Cell Separation and Viewing Instrumentation Supplier
    • 3.1.4. Pharmaceutical/Reagent Supplier
    • 3.1.5. Independent Testing Lab
    • 3.1.6. Public National/regional lab
    • 3.1.7. Hospital lab
    • 3.1.8. Physician Lab
    • 3.1.9. Audit Body
    • 3.1.10. Certification Body

4. Market Trends

  • 4.1. Factors Driving Growth
    • 4.1.1. Outcome potential
    • 4.1.2. Companion Diagnostics
    • 4.1.3. Funding
    • 4.1.4. Technology Environment
    • 4.1.5. Target Solutions
  • 4.2. Factors Limiting Growth
    • 4.2.1. Complex Role of Diagnostics
    • 4.2.2. Clinical Trials Role
    • 4.2.3. Protocols
  • 4.3. Diagnostic Technology Development
    • 4.3.1. Combinations - Issues and Complexity
    • 4.3.2. Shifting Role of Diagnostics
    • 4.3.3. Multiplexing and Foundation One
    • 4.3.4. The Disruption Dynamic
    • 4.3.5. The Race for Biomarkers
    • 4.3.6. The Next Five Years

5. Cancer Immunotherapy Recent Developments

  • 5.1. Recent Developments - Importance and How to Use This Section
    • 5.1.1. Importance of These Developments
    • 5.1.2. How to Use This Section
      • ArcherDx partners with AstraZeneca for Immuno-Oncology
      • Germline Results Guides Precision Therapy
      • Agilent PD-L1 Assay Gets FDA Approval
      • Bayer, OrigiMed Form Companion Diagnostic Development Alliance
      • Bio-Me to Develop Microbiome Biomarker Test for Cancer Immunotherapy
      • SkylineDx, BioInvent Collaborate to Characterize Predictive Immunological
      • Signatures
      • Biocare Medical Launches 7 Novel IVD Antibodies
      • Oncocyte to Acquire Insight Genetics for $12M
      • Novigenix and BioLizard to develop NGS Based Diagnostic Algorithm
      • Biodesix and Immodulon Collaborate for Pancreatic Cancer Treatment
      • Generex to Merge with NuGenerex Immuno-Oncology
      • Cellgen Diagnostics and Genomic Testing Cooperative Partner to Develop
      • Companion Diagnostics for Cancer Therapies
      • Hematogenix Launches FDA Approved Immuno-oncology Test for Triple-Negative
      • Breast Cancer
      • Icon Acquires MolecularMD
      • Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca
      • Tumor Mutational Burden as Predictor of Immunotherapy Success

6. Profiles of Key Immunotherapy Companies

  • 10X Genomics
  • Abbott Laboratories
  • Abcam
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience
  • Angle plc
  • Apocell
  • ARUP Laboratories
  • Beckman Coulter
  • Becton Dickinson
  • Bioarray Genetics
  • BioCartis
  • Biocept
  • Biodesix Inc
  • BioFluidica
  • BioGenex
  • bioMérieux
  • Bio-Rad
  • Bio-Techne
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clearbridge BioMedics
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp
  • CytoTrack
  • Dako (Agilent)
  • Diagnologix LLC
  • Epic Sciences
  • Exosome Diagnostics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • Genomic Health
  • GenomOncology
  • GRAIL
  • Guardant Health
  • HalioDx
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invivoscribe
  • Leica Biosystems
  • Luminex
  • MDx Health
  • Merck & Co., Inc
  • MIODx
  • Molecular MD
  • MRM Proteomics Inc
  • Myriad Genetics/Myriad RBM
  • Nanostring
  • Natera
  • Neogenomics
  • New Oncology
  • Oncocyte
  • Ortho Clinical Diagnostics
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Pfizer
  • Promega
  • Protagen Diagnostics
  • Qiagen
  • Quanterix
  • Rarecells SAS
  • Roche Diagnostics
  • Siemens
  • Silicon Biosystems
  • SkylineDx
  • SRI International
  • Sysmex
  • Thermo Fisher
  • Trovagene
  • Vortex Biosciences

7. The Global Market for Immuno-Oncology Diagnostics

  • 7.1. Global Market Overview by Country
    • 7.1.1. Table - Global Market by Country
    • 7.1.2. Chart - Global Market by Country
  • 7.2. Global Market by Assay Type - Overview
    • 7.2.1. Table - Global Market by Assay Type
    • 7.2.2. Chart - Global Market by Assay Type - Base/Final Year Comparison
    • 7.2.3. Chart - Global Market by Assay Type - Base Year
    • 7.2.4. Chart - Global Market by Assay Type - End Year
    • 7.2.5. Chart - Global Market by Assay Type - Share by Year
    • 7.2.6. Chart - Global Market by Assay Type - Segments Growth

8. Global Immuno-Oncology Diagnostic Markets - By Assay Type

  • 8.1. Checkpoint
    • 8.1.1. Table Checkpoint - by Country
    • 8.1.2. Chart - Checkpoint Growth
  • 8.2. Cytokine
    • 8.2.1. Table Cytokine - by Country
    • 8.2.2. Chart - Cytokine Growth
  • 8.3. Germline Genetic
    • 8.3.1. Table Germline Genetic - by Country
    • 8.3.2. Chart - Germline Genetic Growth
  • 8.4. Genetic Tumor
    • 8.4.1. Table Genetic Tumor - by Country
    • 8.4.2. Chart - Genetic Tumor Growth
  • 8.5. Tumor Microenvironment
    • 8.5.1. Table Tumor Microenvironment - by Country
    • 8.5.2. Chart - Tumor Microenvironment Growth
  • 8.6. Other
    • 8.6.1. Table Other - by Country
    • 8.6.2. Chart - Other Growth

9. Appendices

  • 9.1. FDA Cancer Drug Approvals by Year
  • 9.2. Clinical Trials Started 2010 to 2016
  • 9.3. Prevalence of Cancer Treatments
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.